Review
Open Access

Diagnosis and treatment of hyperemesis gravidarum

Larissa A.W. Jansen, Victoria Shaw, Iris J. Grooten, Marjette H. Koot, Caitlin R. Dean and Rebecca C. Painter
CMAJ April 15, 2024 196 (14) E477-E4485; DOI: https://doi.org/10.1503/cmaj.221502

This article has a correction. Please see:

KEY POINTS

  • Diagnosis of hyperemesis gravidarum can be made in the first 16 weeks of pregnancy when a person has nausea and vomiting, at least 1 of which is severe, impairing sufficient intake and affecting tasks of daily living; the presence of ketonuria is not needed to diagnose hyperemesis gravidarum or determine eligibility for medication.

  • Hyperemesis gravidarum is associated with increased risks of various adverse health outcomes in the short and long term for both pregnant people and their offspring.

  • In the absence of curative options, treatments are aimed at symptom reduction and have the potential to improve quality of life and perinatal outcomes, and to reduce the socioeconomic burden.

  • Treatment with antiemetics has been shown to be effective; evidence for other treatment options is limited.

  • Hyperemesis gravidarum commonly recurs in subsequent pregnancies.

Nausea and vomiting of pregnancy are often considered normal and affect most pregnancies, with 1 meta-analysis finding the average reported rate to be 70%.1 The severe end of the clinical spectrum of nausea and vomiting of pregnancy is called hyperemesis gravidarum.

Hyperemesis gravidarum leads to an inability to eat and drink sufficiently, resulting in weight loss and dehydration. It can have detrimental effects on maternal quality of life2 and may lead to short- and long-term adverse outcomes among offspring. Management of hyperemesis gravidarum requires considerable health care resources, as it is a common reason for hospital admission and emergency department visits in the first trimester.3,4 In the absence of curative options, treatments are aimed at symptom reduction and have the potential to improve quality of life and perinatal outcomes, and to reduce the socioeconomic burden.

We provide an overview of the cause, diagnosis, and treatment of hyperemesis gravidarum, as well as its impact on the birthing parent and offspring (Box 1).

Box 1: Evidence considered in this review

We searched PubMed from inception to 2023 for studies related to the pathophysiology, diagnosis, impact, and treatment of hyperemesis gravidarum. We limited the search to articles in English and focused on randomized clinical trials or systematic reviews, although we did not apply any restrictions on study type. We supplemented this search by screening bibliographies of retrieved articles to identify other relevant articles.

What causes hyperemesis gravidarum?

The cause of hyperemesis gravidarum is not fully understood and is most likely multifactorial. Pregnancy at a young age, pregnancy with a female fetus, multiple pregnancy, molar pregnancy, underlying medical conditions (e.g., thyroid and parathyroid dysfunction, hypercholesterolemia, type 1 diabetes), or a history of hyperemesis gravidarum are associated with an increased risk of hyperemesis gravidarum.5–8 Multiple or molar pregnancy can be ruled out at first presentation with hyperemesis gravidarum using ultrasonography.

Reproductive endocrine and placental factors have been the most extensively investigated as biomarkers associated with the diagnosis and severity of hyperemesis gravidarum.9,10 The role of human chorionic gonadotropin (hCG) has been a focus of research, although a meta-analysis revealed an inconsistent association between the severity of nausea and vomiting of pregnancy and hyperemesis gravidarum with serum concentration of hCG and markers of thyroid dysfunction.11

A recent prospective cohort study showed that 21 (9.8%) of 215 patients with hyperemesis gravidarum had gestational transient thyrotoxicosis, but this was not associated with severity of hyperemesis.10 Gestational transient thyrotoxicosis is caused by stimulation of the maternal thyroid gland by hCG, is self-limiting, and does not generally require treatment. Furthermore, physiologic changes in thyroid function in early pregnancy do not influence the clinical course of hyperemesis gravidarum.10 Therefore, routine testing of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) concentrations is of limited value in patients with hyperemesis gravidarum if no other clinical signs of thyroid disease are present.10 Recently, growth differentiation factor 15 (GDF-15) — which is produced in the early trophoblast and binds receptors in the brain’s “vomiting centre” in the area postrema — was identified as a prime candidate for the link between early placental growth and nausea and vomiting.12,13 A family history of hyperemesis gravidarum is associated with increased risk of the condition, which recent research suggests may be mediated by single nucleotide polymorphisms in the GDF15 gene and the gene of its receptor in the area postrema.14 More research is necessary to verify the role of GDF-15 in the pathogenesis and course of hyperemesis gravidarum.

A 2015 systematic review showed that infection with Helicobacterpylori can be a risk factor for hyperemesis gravidarum.15 Clinicians should also rule out urinary tract infection as a potential cause of nausea and vomiting in pregnancy.16

How is hyperemesis gravidarum defined?

Definitions for hyperemesis gravidarum in clinical and research settings have had a high degree of heterogeneity and historically relied on the presence of ketonuria such as the Fairweather criteria, published in 1968 (Box 2).17,18 However, current evidence does not support the notion that the presence of ketonuria is associated with, or a marker of disease severity for, hyperemesis gravidarum.11,19

Box 2: Diagnosing hyperemesis gravidarum

Fairweather criteria (1968)

  • More than 3 episodes of vomiting a day

  • Weight loss

  • Ketonaemia

  • Electrolyte imbalance

  • Volume depletion

  • Onset usually at 4–8 weeks of pregnancy

Windsor definition (2021)

  • Mandatory features

    • Nausea and vomiting, at least 1 of which is severe

    • Inability to drink or eat normally

    • Strongly affects daily living activities

    • Beginning of symptoms in early pregnancy*

  • Contributory features

    • Signs of dehydration

  • ↵* Early pregnancy was defined as before a gestational age of 16 weeks.

Recently, a multi-stakeholder, international consensus definition of hyperemesis gravidarum was published, the Windsor definition (Box 2).20 This definition was developed to assist in clinical diagnosis and harmonize identification of hyperemesis gravidarum for study populations in clinical trials.

What is the effect of hyperemesis gravidarum on health outcomes?

Birthing parents

The risks of hyperemesis gravidarum and potential management approaches are summarized in Table 1.

View this table:
Table 1:

The risks of hyperemesis gravidarum for pregnant people and their offspring

In the short term, hyperemesis gravidarum can cause substantial weight loss from insufficient caloric intake, as well as dehydration and electrolyte imbalance.32,33 Rarely, vitamin deficiencies can cause severe maternal morbidity or death, including thiamine deficiency, which may lead to Wernicke encephalopathy.23 Malnourishment-related Wernicke encephalopathy in pregnancy is an uncommon, severe, and preventable consequence of hyperemesis gravidarum that warrants attention because of its rapid onset and detrimental course. A systematic review of 177 pregnant patients with hyperemesis gravidarum complicated by Wernicke encephalopathy showed that 50% of fetuses and 5% of the parents died.23 None of these patients had received thiamine treatment; clinicians should be aware that intravenous glucose treatment can precipitate Wernicke encephalopathy.23 Symptoms of the classic Wernicke encephalopathy triad include eye movement disorders (e.g., blurred or double vision, nystagmus, ophthalmoplegia), altered mental status (e.g., confusion, reduced alertness, changes in cognition), and ataxia, but only 60% of patients exhibit the full triad of symptoms.23

Hyperemesis gravidarum increases the risk of both antenatal and postnatal venous thromboembolism.25 Several studies have reported higher rates of depression, anxiety, posttraumatic stress disorder (PTSD), and, in some cases, suicidal ideation among people with hyperemesis gravidarum compared to the general pregnant population.2,26 Furthermore, more than 50% of patients with hyperemesis gravidarum consider terminating a wanted pregnancy, and as many as 11% of patients terminate with hyperemesis gravidarum as the sole reason.28,34

Hyperemesis gravidarum can have health effects that outlast the pregnancy, although evidence is limited. Family planning can be affected, leading to pregnancy being postponed or avoided for fear of recurrent hyperemesis gravidarum.7 Depression and anxiety can persist after pregnancy and symptoms of PTSD have been estimated to affect about 18% of patients with hyperemesis gravidarum, with symptom duration unknown.2

Offspring

In a recent systematic review of 61 studies, we described consequences of hyperemesis gravidarum for the offspring,30 concluding that people with hyperemesis gravidarum were more likely to have a placental abruption (odds ratio [OR] 1.15), a baby with a weight less than 1500 g (OR 1.43), preterm birth (OR 2.81), a baby admitted to neonatal intensive care (OR 1.20), or a baby that required resuscitation (OR 1.07). Hyperemesis gravidarum was associated with fewer stillbirths (OR 0.92) and babies with a birth weight greater than 4000 g (OR 0.74). Whether effective treatment of hyperemesis gravidarum improves these perinatal outcomes is unknown.

Maternal vitamin deficiency as a consequence of hyperemesis gravidarum may lead to neonatal vitamin K deficiency, which results in disordered clotting after birth, and fetal congenital abnormalities.24 Parental undernutrition and weight loss creates a fetal environment that can lead to health effects for offspring over the life course.35 A recent systematic review showed that hyperemesis gravidarum may be associated with small increases in adverse health outcomes among children, including mental health disorders such as anxiety disorders (OR 1.74), sleep problems (OR 2.94) and, possibly, testicular cancer (OR 1.60), although this evidence is based on few studies of low quality.31

When should hyperemesis gravidarum be treated?

Treatment to prevent dehydration and malnutrition is required when nausea and vomiting become so severe as to interfere with normal eating and drinking. Treatment should also be considered when symptoms affect quality of life and activities of daily living.20 Research in the treatment of hyperemesis gravidarum is limited and studies are often small. For instance, comparative effectiveness studies of the 3 most commonly prescribed drugs to treat hyperemesis gravidarum (i.e., antihistamines, metoclopramide, and ondansetron) involved only 552 patients with hyperemesis gravidarum.36

What is the optimal approach to management?

A 2018 Cochrane review of treatments for hyperemesis gravidarum concluded that little high-quality and consistent evidence supports any 1 intervention.37 Management of nausea and vomiting in other conditions can inform strategies for managing hyperemesis gravidarum, although safety considerations for medications used during pregnancy need to be taken into consideration.38 Treatment of hyperemesis gravidarum should initially start with 1 antiemetic drug, and if this is not sufficient to ameliorate nausea, addition of another antiemetic drug of another class has been suggested.21 If the patient shows signs or symptoms of dehydration (e.g., thirst, concentrated urine, dry skin, weakness, lightheadedness, fainting, inability to keep fluids down), clinicians should investigate for electrolyte disturbances and, if necessary, administer intravenous fluid therapy, which should include 100 mg intravenous thiamine supplementation.21 Hospital admission is usually necessary for those with dehydration and marked electrolyte abnormalities, and should be considered if oral and sublingual drugs are insufficiently tolerated or are ineffective, or to facilitate parenteral or intravenous treatment. Thrombosis prophylaxis may be considered in admitted patients, but not all agents used for thrombosis prophylaxis are safe in pregnancy.

Continuity of health care providers over the first and second trimester, as well as between inpatient and outpatient care, can positively affect patients’ physical and mental well-being, and may reduce their requirement for hospital admission and emergency department attendance.4,39 As has been previously suggested,4 an individualized care plan could benefit patients with severe nausea and vomiting in pregnancy.

Evidence on the effectiveness and safety of treatment options for hyperemesis gravidarum are summarized in Table 2 and Table 3.

View this table:
Table 2:

Evidence of the effectiveness and adverse effects of antiemetic treatments for hyperemesis gravidarum

View this table:
Table 3:

Evidence of the effectiveness and adverse effects of other treatments for hyperemesis gravidarum

Antiemetic treatments

Most antiemetic drugs used to treat nausea and vomiting of pregnancy and hyperemesis gravidarum are not approved for use in pregnancy. The only drug approved (in Canada and the United Kingdom) specifically for the treatment of nausea and vomiting of pregnancy is the delayed-release formulation of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg), as this combination has been shown to be more effective than placebo in reducing nausea and vomiting.40,42 A subsequent publication64 questioned the statistical and clinical significance of findings of the study by Koren and colleagues.40 A recent randomized trial found doxylamine–pyridoxine was more effective than placebo in reducing nausea and vomiting.43 However, the clinical importance of this effect is uncertain because of its modest magnitude.

Other first-generation antihistamines such as cyclizine, dimenhydrinate, and promethazine are recommended by some sources, and have been investigated in studies of nausea and vomiting of pregnancy and hyperemesis gravidarum but have not been shown to be more effective than placebo or other treatments.22,37 However, antihistamines can provide an additional anticholinergic benefit to those distressed by hypersalivation in pregnancy.45

If these options fail to control symptoms adequately, other treatments are available, including metoclopramide and ondansetron (Table 2). Concerns about safety have largely been allayed for metoclopramide, but whether use of ondansetron is associated with a slightly increased risk of cleft palate and heart defects — or whether the severity of the indication plays a role in this risk — is unclear. Although route of administration has not been investigated in hyperemesis gravidarum, sublingual or per rectum routes offer the same advantages in other conditions with vomiting.22,65,66

The use of corticosteroids is reserved, especially in the first trimester, for patients for whom symptoms are not adequately controlled with other antiemetics (Table 2).22

Treatment for dehydration

Dehydration, as a consequence of the nausea and vomiting, can be treated by intravenous fluid treatment in either outpatient clinic or inpatient settings, according to local resources and service delivery models.22 Recently, daily intravenous treatment in an outpatient setting (e.g., 2 L of 0.9% sodium chloride solution with 20 mmol of potassium chloride intravenously over 4 h)39 has been shown to be as effective in resolving dehydration as hospital admission and can reduce the length of stay per patient admission and the total number of inpatient nights per year.67 To prevent Wernicke encephalopathy, thiamine supplementation (100 mg/d intravenously) should be offered to all pregnant people with prolonged lack of nutrient intake, especially before administration of dextrose or enteral or parenteral nutrition.22

Nonpharmacologic therapies

People with hyperemesis gravidarum can benefit from avoiding exposure to triggers such as specific odours and particular foods. Old evidence suggests that low-energy, high-protein diets may be associated with a reduction of nausea and vomiting in pregnancy compared with a diet high in carbohydrates.68 Referral to a dietitian could help reduce weight loss and prevent malnutrition.69 Psychosocial support could alleviate the consequences of hyperemesis gravidarum on mood and of limited ability to complete activities of daily living, including caring for young children.70

A 2015 Cochrane review concluded that ginger products, which are considered safe in pregnancy, may be helpful to pregnant people with mild nausea and vomiting, but the evidence of effectiveness was limited and inconsistent for those with hyperemesis gravidarum.44,57 A large online survey study of a self-selected sample of 512 patients admitted to hospital for hyperemesis gravidarum found that the use of ginger produced unpleasant physical adverse effects (e.g., exacerbation of nausea and vomiting, pain or burning during vomiting, acid reflux caused by ginger products) in around half of those who tried it, and was associated with a negative psychological effect in 82% of participants.58

Table 3 lists other nonpharmacologic therapies like acupressure and psychotherapeutic treatment and describes data on their effectiveness and safety.

Other treatment options

Whether eradication of H. pylori prevents or improves symptoms of hyperemesis gravidarum is unclear.15 Eradication of H. pylori requires triple drug therapy (e.g., oral proton pump inhibitor, clarithromycin, and amoxicillin) taken 3 times daily for 7–10 days, so this approach is difficult for those with hyperemesis gravidarum. Eradication before conception may be an attractive method of reducing the risk of recurrent hyperemesis gravidarum in subsequent pregnancies, but its effectiveness in achieving this goal remains unproven and more research is needed.

Other therapeutic agents that can help to manage the condition throughout the pregnancy include proton pump inhibitors, laxatives (particularly if ondansetron causes constipation), and antidepressants (if the condition causes substantial psychological distress).71 Research has suggested that cannabis may provide an antinausea effect in adults with cancer receiving chemotherapy.54 However, use of cannabis in pregnancy has been associated with adverse neurocognitive outcomes in offspring, as well as other adverse pregnancy outcomes.55,56 Therefore, we advise against the use of cannabis in pregnancy.

Iron, frequently prescribed in pregnancy to prevent or treat anemia, may exacerbate nausea, particularly when taken on an empty stomach. One study suggested that the tablet size and not the iron content may affect adherence among patients with nausea and vomiting in pregnancy.72 Temporary discontinuation may be helpful in controlling nausea and vomiting in pregnancy and is not expected to have deleterious effects on the fetus.73 Patients with prolonged discontinuation of iron supplementation may require intravenous iron supplementation.

Management of comorbidities

Conditions such as diabetes, epilepsy, HIV, autoimmune disorders, and psychiatric disorders, or any condition requiring regular oral medication, can be severely affected by comorbid hyperemesis gravidarum. Inability to keep down medication or maintain oral intake can lead to deterioration of these comorbidities. Pregnant people with a history of bariatric surgery may have pre-existing nutritional deficiencies and compromised absorption of oral medication or vitamins, but also need to be urgently assessed for bowel obstruction caused by intestinal herniation if they present with vomiting and abdominal discomfort.74,75

Can hyperemesis gravidarum be prevented?

People with a history of hyperemesis gravidarum in a previous pregnancy are at higher than baseline risk of recurrence. Recurrence rates vary from 15% to 86%, with lower recurrence rates reported in registry studies, which tend to rely on hospital admission for identification of hyperemesis gravidarum, and higher recurrence rates reported in cohort studies which rely on maternal report of symptoms, impact of symptoms, and need for treatment.6,7 A single randomized trial has shown that starting doxylamine succinate and pyridoxine hydrochloride preemptively once pregnancy is confirmed may reduce the overall severity and duration of nausea and vomiting in pregnancy.76

Conclusion

Hyperemesis gravidarum increases the risk of unfavourable health outcomes for pregnant people and their offspring. Treatments are aimed at the alleviation of symptoms, but their impact on improved perinatal outcomes is less clear. Many unanswered questions about the prevention and management of hyperemesis gravidarum remain. In 2021, a prioritized list of questions deemed important to patients and providers was published.77 Understanding the causes of hyperemesis gravidarum and developing more effective treatments were highlighted priorities, along with a greater understanding of the effects of hyperemesis gravidarum and its treatments on both pregnant people and their babies.

Footnotes

  • Competing interests: Iris Grooten and Rebecca Painter are expert members for the development of the Dutch guideline on hyperemesis gravidarum and the thyroid in pregnancy, respectively. Rebecca Painter reports funding from ZonMw, participation on a data safety monitoring board for the CRISTAL study, an advisory position with Stichting ZEHG, and a board position with NVOG. No other competing interests were declared.

  • This article was solicited and has been peer reviewed.

  • Contributors: All of the authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Einarson TR,
    2. Piwko C,
    3. Koren G
    . Quantifying the global rates of nausea and vomiting of pregnancy: a meta-analysis. J Popul Ther Clin Pharmacol 2013;20:e171–83.
    OpenUrlPubMed
  2. ↵
    1. Mitchell-Jones N,
    2. Lawson K,
    3. Bobdiwala S,
    4. et al
    . Association between hyperemesis gravidarum and psychological symptoms, psychosocial outcomes and infant bonding: a two-point prospective case-control multicentre survey study in an inner city setting. BMJ Open 2020;10:e039715.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Gazmararian JA,
    2. Petersen R,
    3. Jamieson DJ,
    4. et al
    . Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol 2002;100:94–100.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Varner CE,
    2. Park AL,
    3. Little D,
    4. et al
    . Emergency department use by pregnant women in Ontario: a retrospective population-based cohort study. CMAJ Open 2020;8:E304–E12.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Fell DB,
    2. Dodds L,
    3. Joseph KS,
    4. et al
    . Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy. Obstet Gynecol 2006;107:277–84.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Fiaschi L,
    2. Nelson-Piercy C,
    3. Tata LJ
    . Hospital admission for hyperemesis gravidarum: a nationwide study of occurrence, reoccurrence and risk factors among 8.2 million pregnancies. Hum Reprod 2016;31:1675–84.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Nijsten K,
    2. Dean C,
    3. van der Minnen LM,
    4. et al
    . Recurrence, postponing pregnancy, and termination rates after hyperemesis gravidarum: follow-up of the MOTHER study. Acta Obstet Gynecol Scand 2021;100:1636–43.
    OpenUrl
  8. ↵
    1. Gabra A
    . Risk factors of hyperemesis gravidarum: review article. Health Sci J 2018;12. doi: 10.21767/1791-809X.1000603.
    OpenUrlCrossRef
  9. ↵
    1. Lee NM,
    2. Saha S
    . Nausea and vomiting of pregnancy. Gastroenterol Clin North Am 2011;40:309–34.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Nijsten K,
    2. Koot MH,
    3. van der Post JAM,
    4. et al
    . Thyroid-stimulating hormone and free thyroxine fail to predict the severity and clinical course of hyperemesis gravidarum: a prospective cohort study. Acta Obstet Gynecol Scand 2021;100:1419–29.
    OpenUrl
  11. ↵
    1. Niemeijer MN,
    2. Grooten IJ,
    3. Vos N,
    4. et al
    . Diagnostic markers for hyperemesis gravidarum: a systematic review and meta-analysis. Am J Obstet Gynecol 2014;211: 150.e1–15.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Moore AG,
    2. Brown DA,
    3. Fairlie WD,
    4. et al
    . The transforming growth factor-β super-family cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000;85:4781–8.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Fejzo M,
    2. Rocha N,
    3. Cimino I,
    4. et al
    . GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature 2024;625:760–7.
    OpenUrl
  14. ↵
    1. Fejzo MS,
    2. Arzy D,
    3. Tian R,
    4. et al
    . Evidence GDF15 plays a role in familial and recurrent hyperemesis gravidarum. Geburtshilfe Frauenheilkd 2018;78:866–70.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Li L,
    2. Li L,
    3. Zhou X,
    4. et al
    . Helicobacter pylori infection is associated with an increased risk of hyperemesis gravidarum: a meta-analysis. Gastroenterol Res Pract 2015;2015:278905.
    OpenUrlPubMed
  16. ↵
    1. Tan PC,
    2. King AS,
    3. Omar SZ
    . Screening for urinary tract infection in women with hyperemesis gravidarum. J Obstet Gynaecol Res 2012;38:145–53.
    OpenUrlPubMed
  17. ↵
    1. Koot MH,
    2. Boelig RC,
    3. Van’t Hooft J,
    4. et al
    . Variation in hyperemesis gravidarum definition and outcome reporting in randomised clinical trials: a systematic review. BJOG 2018;125:1514–21.
    OpenUrlPubMed
  18. ↵
    1. Fairweather DV
    . Nausea and vomiting in pregnancy. Am J Obstet Gynecol 1968;102:135–75.
    OpenUrlPubMed
  19. ↵
    1. Koot MH,
    2. Grooten IJ,
    3. Post J,
    4. et al
    . Ketonuria is not associated with hyperemesis gravidarum disease severity. Eur J Obstet Gynecol Reprod Biol 2020;254:315–20.
    OpenUrlPubMed
  20. ↵
    1. Jansen LAW,
    2. Koot MH,
    3. Van’t Hooft J,
    4. et al
    . The windsor definition for hyperemesis gravidarum: a multistakeholder international consensus definition. Eur J Obstet Gynecol Reprod Biol 2021;266:15–22.
    OpenUrlPubMed
  21. ↵
    1. Smith JA,
    2. Fox KA,
    3. Clark SM
    . Nausea and vomiting of pregnancy: treatment and outcome. UptoDate 2023. Available: https://www.uptodate.com/contents/nausea-and-vomiting-of-pregnancy-treatment-and-outcome#H21389680 (accessed 2024 Feb. 7).
  22. ↵
    1. Nelson-Piercy C,
    2. Dean C,
    3. Shehmar M
    ; the Royal College of Obstetricians and Gynaecologists. The management of nausea and vomiting of pregnancy and hyperemesis gravidarum (Green-top Guideline No. 69). London (UK): John Wiley & Sons; 2024. Available: https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg69-hyperemesis.pdf (accessed 2024 Feb. 7).
  23. ↵
    1. Oudman E,
    2. Wijnia JW,
    3. Oey M,
    4. et al
    . Wernicke’s encephalopathy in hyperemesis gravidarum: a systematic review. Eur J Obstet Gynecol Reprod Biol 2019; 236:84–93.
    OpenUrlPubMed
  24. ↵
    1. Nijsten K,
    2. van der Minnen LM,
    3. Wiegers HMG,
    4. et al
    . Hyperemesis gravidarum and vitamin K deficiency: a systematic review. Br J Nutr 2022;128:30–42.
    OpenUrl
  25. ↵
    1. Fiaschi L,
    2. Nelson-Piercy C,
    3. Gibson J,
    4. et al
    . Adverse maternal and birth outcomes in women admitted to hospital for hyperemesis gravidarum: a population-based cohort study. Paediatr Perinat Epidemiol 2018;32:40–51.
    OpenUrlPubMed
  26. ↵
    1. Nijsten K,
    2. van der Minnen LM,
    3. Dean C,
    4. et al
    . Depression, anxiety, and post-traumatic stress disorder symptoms after hyperemesis gravidarum: a prospective cohort study. J Matern Fetal Neonatal Med 2022;35:10055–10063.
    OpenUrl
    1. Mitchell-Jones N,
    2. Gallos I,
    3. Farren J,
    4. et al
    . Psychological morbidity associated with hyperemesis gravidarum: a systematic review and meta-analysis. BJOG 2017;124:20–30.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Nana M,
    2. Tydeman F,
    3. Bevan G,
    4. et al
    . Hyperemesis gravidarum is associated with increased rates of termination of pregnancy and suicidal ideation: results from a survey completed by >5000 participants. Am J Obstet Gynecol 2021;224:629–31.
    OpenUrlPubMed
    1. Christodoulou-Smith J,
    2. Gold JI,
    3. Romero R,
    4. et al
    . Posttraumatic stress symptoms following pregnancy complicated by hyperemesis gravidarum. J Matern Fetal Neonatal Med 2011;24:1307–11.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Jansen LAW,
    2. Nijsten K,
    3. Limpens J,
    4. et al
    . Perinatal outcomes of infants born to mothers with hyperemesis gravidarum: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2023;284:30–51.
    OpenUrl
  31. ↵
    1. Nijsten K,
    2. Jansen LAW,
    3. Limpens J,
    4. et al
    . Long-term health outcomes of children born to mothers with hyperemesis gravidarum: a systematic review and meta-analysis. Am J Obstet Gynecol 2022;227:414–429.e17.
    OpenUrl
  32. ↵
    1. Birkeland E,
    2. Stokke G,
    3. Tangvik RJ,
    4. et al
    . Norwegian PUQE (Pregnancy-Unique Quantification of Emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: a prospective cohort validation study. PLoS One 2015;10:e0119962.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Grooten IJ,
    2. Roseboom TJ,
    3. Painter RC
    . Barriers and challenges in hyperemesis gravidarum research. Nutr Metab Insights 2016;8(Suppl 1):33–9.
    OpenUrlPubMed
  34. ↵
    1. Poursharif B,
    2. Korst LM,
    3. Macgibbon KW,
    4. et al
    . Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum. Contraception 2007;76:451–5.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Bateson P,
    2. Barker D,
    3. Clutton-Brock T,
    4. et al
    . Developmental plasticity and human health. Nature 2004;430:419–21.
    OpenUrlCrossRefPubMed
  36. ↵
    1. O’Donnell A,
    2. McParlin C,
    3. Robson SC,
    4. et al
    . Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment. Health Technol Assess 2016;20:1–268.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Boelig RC,
    2. Barton SJ,
    3. Saccone G,
    4. et al
    . Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J Matern Fetal Neonatal Med 2018;31:2492–505.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Hendren G,
    2. Aponte-Feliciano A,
    3. Kovac A
    . Safety and efficacy of commonly used antiemetics. Expert Opin Drug Metab Toxicol 2015;11:1753–67.
    OpenUrl
  39. ↵
    1. Mitchell-Jones N,
    2. Farren JA,
    3. Tobias A,
    4. et al
    . Ambulatory versus inpatient management of severe nausea and vomiting of pregnancy: a randomised control trial with patient preference arm. BMJ Open 2017;7:e017566.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Koren G,
    2. Clark S,
    3. Hankins GD,
    4. et al
    . Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 2010;203:571.e1–7.
    OpenUrlPubMed
    1. Magee LA,
    2. Mazzotta P,
    3. Koren G
    . Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002;186(5 Suppl Understanding):S256–61.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Madjunkova S,
    2. Maltepe C,
    3. Koren G
    . The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin®) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs 2014;16:199–211.
    OpenUrl
  43. ↵
    1. Wu XK,
    2. Gao JS,
    3. Ma HL,
    4. et al
    . Acupuncture and doxylamine-pyridoxine for nausea and vomiting in pregnancy: a randomized, controlled, 2 × 2 factorial trial. Ann Intern Med 2023;176:922–33.
    OpenUrl
  44. ↵
    1. Matthews A,
    2. Haas DM,
    3. O’Mathúna DP,
    4. et al
    . Interventions for nausea and vomiting in early pregnancy. Cochrane Data Syst Rev 2015;2015(9):CD007575.
    OpenUrl
  45. ↵
    1. Schaefer TS,
    2. Zito PM
    . Antiemetic histamine H1 receptor blockers. Treasure Island (FL): StatPearls;2022.
    1. Gilboa SM,
    2. Ailes EC,
    3. Rai RP,
    4. et al
    . Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf 2014;13:1667–98.
    OpenUrlCrossRefPubMed
    1. Mohammadbeigi R,
    2. Shahgeibi S,
    3. Soufizadeh N,
    4. et al
    . Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea. Pak J Biol Sci 2011;14:817–20.
    OpenUrlPubMed
    1. Sun L,
    2. Xi Y,
    3. Wen X,
    4. et al
    . Use of metoclopramide in the first trimester and risk of major congenital malformations: a systematic review and meta-analysis. PLoS One 2021;16:e0257584.
    OpenUrl
    1. Bérard A,
    2. Sheehy O,
    3. Gorgui J,
    4. et al
    . New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. J Clin Epidemiol 2019;116:39–48.
    OpenUrl
    1. Oliveira LG,
    2. Capp SM,
    3. You WB,
    4. et al
    . Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. Obstet Gynecol 2014;124:735–42.
    OpenUrl
    1. Kashifard M,
    2. Basirat Z,
    3. Kashifard M,
    4. et al
    . Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study. Clin Exp Obstet Gynecol 2013;40:127–30.
    OpenUrl
    1. Picot C,
    2. Berard A,
    3. Grenet G,
    4. et al
    . Risk of malformation after ondansetron in pregnancy: an updated systematic review and meta-analysis. Birth Defects Res 2020;112:996–1013.
    OpenUrl
    1. Huybrechts KF,
    2. Hernandez-Diaz S,
    3. Straub L,
    4. et al
    . Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA 2018;320:2429–37.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Smith LA,
    2. Azariah F,
    3. Lavender VTC,
    4. et al
    . Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Data Syst Rev 2015;2015(11):CD009464.
    OpenUrl
  55. ↵
    1. Badowski S,
    2. Smith G
    . Cannabis use during pregnancy and postpartum. Can Fam Physician 2020;66:98–103.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Koren G,
    2. Cohen R
    . The use of cannabis for hyperemesis gravidarum (HG). J Cannabis Res 2020;2:4.
    OpenUrlPubMed
  57. ↵
    1. Viljoen E,
    2. Visser J,
    3. Koen N,
    4. et al
    . A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J 2014;13:20.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Dean CR,
    2. O’Hara ME
    . Ginger is ineffective for hyperemesis gravidarum, and causes harm: an Internet-based survey of sufferers. MIDIRS 2015;25:6.
    OpenUrl
    1. Park J,
    2. Sohn Y,
    3. White AR,
    4. et al
    . The safety of acupuncture during pregnancy: a systematic review. Acupunct Med 2014;32:257–66.
    OpenUrlCrossRefPubMed
    1. Emami-Sahebi A,
    2. Elyasi F,
    3. Yazdani-Charati J,
    4. et al
    . Psychological interventions for nausea and vomiting of pregnancy: a systematic review. Taiwan J Obstet Gynecol 2018;57:644–9.
    OpenUrl
    1. Nava-Ocampo AA,
    2. Velázquez-Armenta EY,
    3. Han JY,
    4. et al
    . Use of proton pump inhibitors during pregnancy and breastfeeding. Can Fam Physician 2006;52:853–4.
    OpenUrlAbstract/FREE Full Text
    1. Ostenfeld A,
    2. Petersen TS,
    3. Futtrup TB,
    4. et al
    . Validating the effect of Ondansetron and Mirtazapine in Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial. BMJ Open 2020;10:e034712.
    OpenUrlAbstract/FREE Full Text
    1. Gao SY,
    2. Wu QJ,
    3. Sun C,
    4. et al
    . Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med 2018;16:205.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Persaud N,
    2. Meaney C,
    3. El-Emam K,
    4. et al
    . Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo-controlled trial: prespecified analyses and reanalysis. PLoS One 2018;13:e0189978.
    OpenUrl
  65. ↵
    1. Derry CJ,
    2. Derry S,
    3. Moore RA
    . Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2012(2) CD009664.
    OpenUrl
  66. ↵
    1. Fumoleau P,
    2. Giovannini M,
    3. Rolland F,
    4. et al
    . Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group. Oral Oncol 1997;33:354–8.
    OpenUrlPubMed
  67. ↵
    1. Ucyigit MA
    . Outpatient management of hyperemesis gravidarum and the impact on inpatient admissions; a retrospective observational study. Eur J Obstet Gynecol Reprod Biol 2020;254:298–301.
    OpenUrl
  68. ↵
    1. Jednak MA,
    2. Shadigian EM,
    3. Kim MS,
    4. et al
    . Protein meals reduce nausea and gastric slow wave dysrhythmic activity in first trimester pregnancy. Am J Physiol 1999;277:G855–61.
    OpenUrlPubMed
  69. ↵
    1. Maslin K,
    2. Billson HA,
    3. Dean CR,
    4. et al
    . The contribution of registered dietitians in the management of hyperemesis gravidarum in the United Kingdom. Nutrients 2021;13:1964.
    OpenUrl
  70. ↵
    1. Havnen GC,
    2. Truong MB,
    3. Do MH,
    4. et al
    . Women’s perspectives on the management and consequences of hyperemesis gravidarum - a descriptive interview study. Scand J Prim Health Care 2019;37:30–40.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Dean CR,
    2. Shemar M,
    3. Ostrowski GAU,
    4. et al
    . Management of severe pregnancy sickness and hyperemesis gravidarum. BMJ 2018;363:k5000.
    OpenUrlFREE Full Text
  72. ↵
    1. Nguyen P,
    2. Nava-Ocampo A,
    3. Levy A,
    4. et al
    . Effect of iron content on the tolerability of prenatal multivitamins in pregnancy. BMC Pregnancy Childbirth 2008;8:17.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Koren G,
    2. Pairaideau N
    . Compliance with prenatal vitamins. Patients with morning sickness sometimes find it difficult. Can Fam Physician 2006;52:1392–3.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Slater C,
    2. Morris L,
    3. Ellison J,
    4. et al
    . Nutrition in pregnancy following bariatric surgery. Nutrients 2017;9:1338.
    OpenUrl
  75. ↵
    1. Leal-González R,
    2. De la Garza-Ramos R,
    3. Guajardo-Pérez H,
    4. et al
    . Internal hernias in pregnant women with history of gastric bypass surgery: case series and review of literature. Int J Surg Case Rep 2013;4:44–7.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Maltepe C,
    2. Koren G
    . Preemptive treatment of nausea and vomiting of pregnancy: results of a randomized controlled trial. Obstet Gynecol Int 2013; 2013:809787.
    OpenUrlPubMed
  77. ↵
    1. Dean CR,
    2. Bierma H,
    3. Clarke R,
    4. et al
    . A patient-clinician James Lind Alliance partnership to identify research priorities for hyperemesis gravidarum. BMJ Open 2021;11:e041254.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Canadian Medical Association Journal: 196 (14)
CMAJ
Vol. 196, Issue 14
15 Apr 2024

Article tools

Respond to this article
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Diagnosis and treatment of hyperemesis gravidarum
Larissa A.W. Jansen, Victoria Shaw, Iris J. Grooten, Marjette H. Koot, Caitlin R. Dean, Rebecca C. Painter
CMAJ Apr 2024, 196 (14) E477-E4485; DOI: 10.1503/cmaj.221502
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Collections

Get the latest content from Canada's leading medical journal, free to all physicians. Click to sign up for CMAJ or JAMC email alerts.

 

View Latest Classified Ads